Several studies designed GRP78-binding peptides conjugated with cytotoxic drugs to precisely target cancer cells, which demonstrated promising results in vitro and in vivo (Arap et al., 2004; Kim et al., 2006; Yoneda et al., 2008). This evidence concerns the gene HSPA5 and cancer.